Anti-Amyloid Fibril antibody [mOC87] - Conformation-Specific
- BOND RX™ Validated
- 20ul selling size
- RabMAb
- Recombinant
- What is this?
5
(2 Reviews)
|
(14 Publications)
Rabbit Recombinant Monoclonal Amyloid-beta precursor protein antibody. Suitable for Dot, IHC-P, IHC-FrFl and reacts with Synthetic peptide, Human, Mouse samples. Cited in 14 publications.
View Alternative Names
A4, AD1, APP, Amyloid-beta precursor protein, ABPP, APPI, Alzheimer disease amyloid A4 protein homolog, Alzheimer disease amyloid protein, Amyloid precursor protein, Amyloid-beta (A4) precursor protein, Amyloid-beta A4 protein, Cerebral vascular amyloid peptide, PreA4, Protease nexin-II, CVAP, PN-II
- IHC-P
Lab
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Amyloid Fibril antibody [mOC87] - Conformation-Specific (AB201062)
IHC image of beta Amyloid staining in human Alzheimer hippocampus formalin fixed paraffin embedded tissue section* performed on a Leica Bond™ system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6 epitope retrieval solution 1) for 20 mins. The section was then incubated with ab201062 1μg/ml for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions primary antibody concentration and antibody incubation times.
*Tissue obtained from the Human Research Tissue Bank supported by the NIHR Cambridge Biomedical Research Centre
- IHC-FrFl
Collaborator
Immunohistochemistry - Free Floating - Anti-Amyloid Fibril antibody [mOC87] - Conformation-Specific (AB201062)
Immunohistochemical staining of human brain tissue from a patient with a diagnosis of Alzheimers disease male 81 years 5 hour post mortem index tangle stage 5 plaque stage B mini mental status exam score 12. Sections were cut using a vibratome. No antigen retrieval was performed. Free floating sections were stained using ab201062 at a dilution of 50 ng/mL. The secondary antibody used was a biotinylated goat anti-rabbit at a dilution of 1/225 which was blocked with normal goat serum. The sample was visualized using ABC solution (1 hour incubation) followed by 1-4 minutes of DAB. The sample was mounted and allowed to dry overnight followed by dehydration in increasingly concentrated ethanol solutions.
Image courtesy of Professor Charles Glabe, UC Irvine
- Dot
Supplier Data
Dot Blot - Anti-Amyloid Fibril antibody [mOC87] - Conformation-Specific (AB201062)
Negative control (secondary ab only) :
Lane 1 : beta Amyloid (Aβ) 1-40.
Lane 2 : beta Amyloid (Aβ) 1-42.
Goat Anti-Rabbit IgG (H+L) Peroxidase conjugated (ab97051) at 1/5000 dilution was used as secondary antibody.
Blocking and diluting buffer : 5% NFDM/TBST.
Exposure time : 30 seconds.
- Dot
Supplier Data
Dot Blot - Anti-Amyloid Fibril antibody [mOC87] - Conformation-Specific (AB201062)
Dot blot analysis of beta Amyloid 1-42 labeled with ab201062 at 1/8000 dilution.
Lane 1 : beta Amyloid (Aβ) 1-40.
Lane 2 : beta Amyloid (Aβ) 1-42.
Goat Anti-Rabbit IgG (H+L) Peroxidase conjugated (ab97051) at 1/5000 dilution was used as secondary antibody.
Blocking and diluting buffer : 5% NFDM/TBST.
Exposure time : 30 seconds.
Antibody reactivity was assessed using a dot blot which is a non-quantitative method that maintains the native conformation of beta Amyloid. Beta Amyloid 1-40 and 1-42 peptides underwent the following aggregation conditions before being spotted onto a nitrocellulose membrane and detected using ab201062 :
Monomers : 0.3 mg of beta Amyloid peptide was dissolved in 30 μl 100 mM NaOH and incubated at room temperature for 10 minutes. It was then diluted with 970 μl of 1% SDS and boiled for five minutes.
Oligomers : 0.3 mg of beta Amyloid peptide was dissolved in 30 μl 100 mM NaOH and incubated at room temperature for 10 minutes. It was then diluted with 970 μl of 10 mM phosphate buffer pH 7.4 containing 0.02% sodium azide and incubated at room temperature for four days.
Fibrils : 0.3 mg of beta Amyloid peptide was dissolved in 1 ml 50% hexafluoroisopropanol (HFIP) with 0.02% sodium azide. It was then stirred constantly for nine days; the first seven with a cap on and the final two with the cap removed to allow evaporation of the HFIP. Fibrils were then sedimented at 20000 rpm in a microcentrifuge for 20 minutes and resuspended in 1 ml of PBS + 0.02% sodium azide.
Related conjugates and formulations (1)
-
Anti-Amyloid Fibril antibody [mOC87] - BSA and Azide free
Reactivity data
Product details
This antibody was developed as part of a collaboration between Abcam and Professor Charles Glabe, UC Irvine.
ab201062 recognizes a generic epitope of amyloid fibrils and oligomers that is independent of linear sequence (Hatami et al. 2014, PMID: 25281743). Its reactivity with Aß monomer and oligomers is decreased or eliminated upon thermal denaturation at 100°C of Aß in SDS sample buffer on western blots (Hatami et al. 2014, PMID: 25281743).
For further information on the immunogen, please refer to Hatami et al. 2014, PMID: 25281743 and Kayed et al. 2007, PMID: 17897471.
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
The misfolding and accumulation of proteins into amyloid fibrils prove disruptive within cells. These aggregates often form as part of complex protein assemblies and interfere with normal cellular functions. This disruption further leads to cellular dysfunction and death. While commonly observed in neuronal cells where they are linked to neurodegenerative conditions amyloid fibrils can also appear in other tissues and organs suggesting multi-systemic implications.
Pathways
Scientists recognize amyloid fibrils for their involvement in the amyloidogenic pathways. These pathways often lead to the generation and accumulation of misfolded proteins. The amyloid precursor protein (APP) and presenilins play important roles in pathway processes associated with amyloid fibrils. In addition the fibrillar structures can influence calcium dysregulation and oxidative stress contributing to altered cellular homeostasis.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (14)
Recent publications for all applications. Explore the full list and refine your search
Journal of neurochemistry 169:e70082 PubMed40377064
2025
Applications
Unspecified application
Species
Unspecified reactive species
Journal of neuroinflammation 22:119 PubMed40275379
2025
Applications
Unspecified application
Species
Unspecified reactive species
NPJ Parkinson's disease 10:194 PubMed39443520
2024
Applications
Unspecified application
Species
Unspecified reactive species
Nature communications 15:8748 PubMed39384788
2024
Applications
Unspecified application
Species
Unspecified reactive species
Phytotherapy research : PTR 38:4815-4831 PubMed39225174
2024
Applications
Unspecified application
Species
Unspecified reactive species
Journal of neurochemistry 168:1193-1214 PubMed38372586
2024
Applications
Unspecified application
Species
Unspecified reactive species
Nature communications 14:5718 PubMed37714837
2023
Applications
Unspecified application
Species
Unspecified reactive species
Small (Weinheim an der Bergstrasse, Germany) 19:e2205634 PubMed36748326
2023
Applications
Unspecified application
Species
Unspecified reactive species
Acta pharmaceutica Sinica. B 12:1723-1739 PubMed35847494
2022
Applications
Unspecified application
Species
Unspecified reactive species
The Journal of biological chemistry 296:100168 PubMed33298522
2020
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com